Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.

被引：0
|
作者：
Jin, Min [1 ]
Yang, Shengli [1 ]
Liu, Junli [1 ]
Zhang, Jieying [1 ]
Zhao, Lei [1 ]
Yu, Dandan [1 ]
Lin, Zhenyu [1 ]
Li, Pindong [1 ]
Wang, Jing [1 ]
Xue, Jun [1 ]
Ma, Hong [1 ]
Hu, Jianli [1 ]
Zhang, Tao [1 ]
Liu, Hongli [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
3282-3306-3348-4026; 261-492-3532-2370-7650-2700; 130-540-543-12277-2683; 613-135-244-3829; 261-492-3532-2370-5109; 613-225-3248-9559-9794-11285; 4; 3; 2; 2461; 2444; 1704; 5; 38116-38094-8;
D O I：
10.1200/JCO.2024.42.3_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [31] Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
    Jiang, Man
    Zhang, Chuantao
    Hu, Yabin
    Li, Tianjun
    Yang, Guangjie
    Wang, Guanqun
    Zhu, Jingjuan
    Shao, Changfeng
    Hou, Helei
    Zhou, Na
    Liu, Kewei
    Zhang, Xiaochun
    ONCOLOGIST, 2022, 27 (11): : E856 - E869
  • [32] Camrelizumab combined with SOX in the first-line treatment of unresectable advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, prospective, and open-label clinical study.
    Liu, Wenlou
    Qin, Xiaobing
    Zhao, Yang
    Ge, Yan
    Tang, Juanjuan
    Wang, Hongmei
    Han, Zhengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16090 - E16090
  • [33] Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer.
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16016 - E16016
  • [34] Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study.
    Xu, Rui-Hua
    Wang, Feng
    Shen, Lin
    Guo, Weijian
    Liu, Tianshu
    Li, Jin
    Qin, Shukui
    Bai, Yuxian
    Chen, Zhendong
    Wang, Jufeng
    Pan, Yueyin
    Shu, Yongqian
    Zhao, Fuyou
    Cheng, Ying
    Ye, Feng
    Gu, Kangsheng
    Zhang, Tao
    Pan, Hongming
    Zhong, Haijun
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (36_SUPPL) : 438780 - 438780
  • [35] Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
    Schlintl, Verena
    Huemer, Florian
    Greil, Richard
    Weiss, Lukas
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (02) : 906 - 909
  • [36] Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study
    Lu, M.
    Yu, X.
    Chen, Z.
    Zhang, Y.
    Li, Z.
    Zhang, X.
    Yin, F.
    Ye, F.
    Cheng, Y.
    Song, L.
    Xu, J.
    Zhou, J.
    Shi, H.
    Tan, P.
    Fan, S.
    Su, W.
    Shen, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1448 - S1448
  • [37] Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction
    Zhang, Fengli
    Yin, Yanfen
    Ni, Tiantian
    Zhang, Mei
    Zhou, Zhou
    Sun, Xin
    Kuang, Wanghao
    Li, Ping
    PHARMAZIE, 2020, 75 (08): : 389 - 394
  • [38] Tumor Treating Fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial
    Li, J.
    Cang, S.
    Ling, Y.
    Lam, K. O.
    Chen, Y.
    Xu, Y.
    Yang, Y.
    Lavy-Shahaf, G.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1455 - S1455
  • [39] Sintilimab combined sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase II study.
    Wang, Jiabei
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16182 - E16182
  • [40] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li Ning
    Li Zhi
    Fu Qiang
    Zhang Bin
    Zhang Jian
    Wan XiangBin
    Lu Chaomin
    Wang Jinbang
    Deng Wenying
    Wei Chen
    Ma Yijie
    Bie Liangyu
    Wang Mengyu
    Luo Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345